BHOCBiological Hemoglobin Oxygen Carrier
Transplant research

Ischemia-reperfusion injury in transplantation

Explore ischemia-reperfusion injury, mitochondrial oxygen use and organ-specific outcomes in kidney, liver, heart and lung transplantation.

What is ischemia-reperfusion injury?

Ischemia-reperfusion injury is tissue injury associated with the interruption and restoration of blood flow. In transplantation, an organ passes through donor recovery, transport, preparation and implantation. The conditions at each stage affect how it responds when oxygenated flow returns.

Reperfusion is necessary for the organ to function. Its effects need to be measured at the tissue level and after transplantation. The time of a measurement matters. An early biochemical signal and an outcome months later describe different parts of the organ's recovery.

Succinate and the return of oxygen

Chouchani and colleagues found that succinate accumulated during ischemia in experimental tissues. Its rapid oxidation during reperfusion drove mitochondrial reactive oxygen species production through reverse electron transport at complex I.

The intervention experiments included mouse models of heart attack and stroke. They provide a mechanism for studying the return of oxygen. Transplantation studies must still establish how that mechanism relates to a particular donor organ, perfusion protocol and recipient outcome.

Liver perfusion and mitochondrial measurements

Schlegel and colleagues studied mitochondrial injury during oxygenated liver perfusion. In rat livers, succinate exposure caused more flavin mononucleotide (FMN) release under normothermic conditions than under cold conditions. Their human component examined FMN and NADH in perfusate during hypothermic oxygenated perfusion of livers donated after circulatory death.

The DHOPE-DCD randomized trial followed a clinical outcome. It compared hypothermic oxygenated perfusion with static cold storage and measured nonanastomotic biliary strictures within six months after transplantation. This connects the research programme to a defined bile-duct complication.

Kidneys and delayed graft function

In the paired-kidney trial by Moers and colleagues, one kidney from each of 336 deceased donors received hypothermic machine perfusion and the other received cold storage. The primary endpoint was delayed graft function, defined as dialysis in the first week after transplantation.

Delayed graft function occurred in 70 machine-perfused kidneys and 89 cold-stored kidneys. The trial also tracked creatinine, rejection and graft survival. Those separate endpoints help describe recovery. Dialysis use alone does not establish the mechanism responsible for impaired graft function.

Lungs and function after EVLP

Cypel and colleagues evaluated high-risk donor lungs during four hours of normothermic ex vivo lung perfusion (EVLP). Lungs from 20 of the 23 donors assessed with EVLP were transplanted. The prospective study used a nonrandomized comparison with lungs transplanted during the same period.

Its primary endpoint was primary graft dysfunction at 72 hours. The observed difference between groups was not statistically significant. Gas exchange during EVLP and graft dysfunction after implantation were measured at different stages. Both belong in the study record.

Hearts and the chosen follow-up period

PROCEED II randomized 130 heart-transplant candidates to donor hearts transported with the Organ Care System or standard cold storage. It was a non-inferiority trial with a primary endpoint of patient and graft survival at 30 days.

That endpoint describes short-term transplant outcomes. It does not directly quantify mitochondrial injury during transport. A heart-perfusion study needs to identify which measurements assess the organ on the circuit and which assess its performance in the recipient.

A defined question for BHOC Transplant

Within Precision Oxygen Therapeutics, BHOC Transplant proposes research on oxygen delivery adapted to tissue demand. A study of Biological Hemoglobin Oxygen Carrier would specify formulation, temperature, flow, oxygen unloading and the organ being studied.

The research question should connect those conditions with measured tissue injury and organ function. Clinical studies would also require predefined recipient outcomes and follow-up. The external studies discussed here help frame that work. Product-specific results require a BHOC study.

Related research